We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
Curing Autism and Other Cerebral Folate Deficiencies.
Cox is a phase III pharmaceutical company developing proprietary treatments for autism and other cerebral folate deficiencies. Cox has formulated levoleucovorin into a new liquid dosage format for its most advanced clinical program, and is building off of ground-breaking clinical research from Autism Speaks to move directly into phase III clinical development. The company was founded based on pioneering research at Downstate Medical Center and the discovery of an autoimmune response that inhibits folate transport to the brain in conditions such as autism. Several clinical studies and case reports have demonstrated that high dose reduced folates are capable of overcoming the folate block induced by this immune response, and overcoming language and other neurological deficits in autistic children. Optimum folate therapies are, however, not available to treat children when they are first diagnosed with autism. Cox’s first drug product, LL-One, is a liquid solution of levoleucovorin designed for optimum treatment of autistic children of all ages. The formulation and method of treatment are protected by two granted patents and two pending applications in the United States with corresponding protection around the world.